[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.
La direttrice di Ionis Pharmaceuticals, B. Lynne Parshall, ha venduto 5,000 azioni ordinarie di Ionis il 08/06/2025 nell'ambito di un piano di negoziazione predefinito ai sensi della Regola 10b5-1 adottato il 6 maggio 2025. Le comunicazioni riportano due vendite: 4,600 azioni a un prezzo medio ponderato di $41.8685 (i singoli prezzi sono variati da $41.50 a $42.36) e 400 azioni a un prezzo medio ponderato di $42.6275 (i prezzi individuali sono variati da $42.56 a $42.83). A seguito delle operazioni segnalate, il Form 4 indica una partecipazione beneficiaria rispettivamente di 86,744 azioni e 86,344 azioni. La persona che ha presentato la comunicazione 猫 indicata come direttrice e le vendite sono state eseguite conformemente al piano di negoziazione reso noto.
B. Lynne Parshall, directora de Ionis Pharmaceuticals, vendi贸 5,000 acciones ordinarias de Ionis el 08/06/2025 bajo un plan de negociaci贸n preestablecido conforme a la Regla 10b5-1 adoptado el 6 de mayo de 2025. Los informes registran dos ventas: 4,600 acciones a un precio medio ponderado de $41.8685 (los precios individuales oscilaron entre $41.50 y $42.36) y 400 acciones a un precio medio ponderado de $42.6275 (los precios individuales oscilaron entre $42.56 y $42.83). Tras las operaciones comunicadas, el Form 4 muestra una participaci贸n beneficiaria de 86,744 acciones y 86,344 acciones, respectivamente. La persona informante figura como directora y las ventas se realizaron de conformidad con el plan de negociaci贸n divulgado.
Ionis Pharmaceuticals鞚� 鞚挫偓 B. Lynne Parshall電� 2025雲� 08/06鞐� 靷爠鞐� 靹れ爼霅� Rule 10b5-1 瓯半灅瓿勴殟(2025雲� 5鞗� 6鞚� 毂勴儩)鞐� 霐半澕 Ionis 氤错喌欤� 5,000欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 霊� 瓯挫潣 毵る弰臧� 氤搓碃霅橃柎 鞛堨姷雼堧嫟: 臧�欷戫弶攴� 臧�瓴� $41.8685搿� 4,600欤�(臧滊硠 瓯半灅 臧�瓴� 氩旍渼: $41.50鈥�$42.36)鞕� 臧�欷戫弶攴� 臧�瓴� $42.6275搿� 400欤�(臧滊硠 瓯半灅 臧�瓴� 氩旍渼: $42.56鈥�$42.83). 氤搓碃霅� 瓯半灅 頉� Form 4鞐愲姅 臧侁皝 86,744欤检檧 86,344欤检潣 鞁れ鞝� 靻岇湢(bene铿乧ial ownership) 靾橃箻臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚胳潃 鞚挫偓搿� 氇呾嫓霅橃柎 鞛堨溂氅�, 毵る弰電� 瓿店皽霅� 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
B. Lynne Parshall, administratrice d'Ionis Pharmaceuticals, a vendu 5,000 actions ordinaires d'Ionis le 08/06/2025 en vertu d'un plan de n茅gociation pr茅茅tabli au titre de la r猫gle 10b5-1 adopt茅 le 6 mai 2025. Les d茅clarations font 茅tat de deux ventes : 4,600 actions 脿 un prix moyen pond茅r茅 de $41.8685 (les prix individuels allant de $41.50 脿 $42.36) et 400 actions 脿 un prix moyen pond茅r茅 de $42.6275 (prix individuels de $42.56 脿 $42.83). 脌 la suite des transactions signal茅es, le Form 4 indique des positions de propri茅t茅 b茅n茅ficiaire de 86,744 actions et 86,344 actions, respectivement. La personne d茅clarante est identifi茅e comme administratrice et les ventes ont 茅t茅 ex茅cut茅es conform茅ment au plan de n茅gociation divulgu茅.
Die Direktorin von Ionis Pharmaceuticals, B. Lynne Parshall, verkaufte am 08/06/2025 5,000 Stammaktien von Ionis im Rahmen eines vorab festgelegten Handelsplans nach Rule 10b5-1, der am 6. Mai 2025 angenommen wurde. Die Meldungen berichten von zwei Verk盲ufen: 4,600 Aktien zu einem gewichteten Durchschnittspreis von $41.8685 (Einzelhandelspreise lagen zwischen $41.50 und $42.36) und 400 Aktien zu einem gewichteten Durchschnittspreis von $42.6275 (Einzelpreise zwischen $42.56 und $42.83). Nach den gemeldeten Transaktionen weist das Form 4 jeweils 86,744 Aktien bzw. 86,344 Aktien als wirtschaftliches Eigentum aus. Die meldende Person ist als Direktorin angegeben, und die Verk盲ufe wurden gem盲脽 dem offengelegten Handelsplan ausgef眉hrt.
- Sales executed under a Rule 10b5-1 trading plan, indicating the transactions were pre-authorized and reduce concerns about opportunistic timing.
- Filing provides weighted-average prices and explicit price ranges and offers to supply detailed breakdowns, which supports transparency.
- None.
Insights
TL;DR: Director sales under a 10b5-1 plan are routine and signal pre-planned disposition, not necessarily a change in company outlook.
The Form 4 documents two sales by Director B. Lynne Parshall totaling 5,000 shares executed on 08/06/2025 under a Rule 10b5-1 trading plan adopted May 6, 2025. This structure typically provides an affirmative defense against insider trading claims and indicates transactions were pre-authorized. The filing also includes weighted-average prices and price ranges, and offers to provide transaction-level breakdowns on request, which supports transparency in disclosure practices. Impact on investors is limited absent additional context on relative stake size or company developments.
TL;DR: The sales are a disclosed insider disposition with clear pricing; unlikely to be materially market-moving on their own.
The Form 4 shows routine sales of 4,600 and 400 shares at weighted-average prices of $41.8685 and $42.6275, with specified price ranges. The reporting person remains a director after the transactions, and the filing includes explicit post-transaction beneficial ownership figures. Because the transactions were conducted pursuant to a documented 10b5-1 plan and the filing provides price-range transparency, these disclosures reduce uncertainty but do not by themselves convey a material operational or financial change for Ionis Pharmaceuticals.
La direttrice di Ionis Pharmaceuticals, B. Lynne Parshall, ha venduto 5,000 azioni ordinarie di Ionis il 08/06/2025 nell'ambito di un piano di negoziazione predefinito ai sensi della Regola 10b5-1 adottato il 6 maggio 2025. Le comunicazioni riportano due vendite: 4,600 azioni a un prezzo medio ponderato di $41.8685 (i singoli prezzi sono variati da $41.50 a $42.36) e 400 azioni a un prezzo medio ponderato di $42.6275 (i prezzi individuali sono variati da $42.56 a $42.83). A seguito delle operazioni segnalate, il Form 4 indica una partecipazione beneficiaria rispettivamente di 86,744 azioni e 86,344 azioni. La persona che ha presentato la comunicazione 猫 indicata come direttrice e le vendite sono state eseguite conformemente al piano di negoziazione reso noto.
B. Lynne Parshall, directora de Ionis Pharmaceuticals, vendi贸 5,000 acciones ordinarias de Ionis el 08/06/2025 bajo un plan de negociaci贸n preestablecido conforme a la Regla 10b5-1 adoptado el 6 de mayo de 2025. Los informes registran dos ventas: 4,600 acciones a un precio medio ponderado de $41.8685 (los precios individuales oscilaron entre $41.50 y $42.36) y 400 acciones a un precio medio ponderado de $42.6275 (los precios individuales oscilaron entre $42.56 y $42.83). Tras las operaciones comunicadas, el Form 4 muestra una participaci贸n beneficiaria de 86,744 acciones y 86,344 acciones, respectivamente. La persona informante figura como directora y las ventas se realizaron de conformidad con el plan de negociaci贸n divulgado.
Ionis Pharmaceuticals鞚� 鞚挫偓 B. Lynne Parshall電� 2025雲� 08/06鞐� 靷爠鞐� 靹れ爼霅� Rule 10b5-1 瓯半灅瓿勴殟(2025雲� 5鞗� 6鞚� 毂勴儩)鞐� 霐半澕 Ionis 氤错喌欤� 5,000欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 霊� 瓯挫潣 毵る弰臧� 氤搓碃霅橃柎 鞛堨姷雼堧嫟: 臧�欷戫弶攴� 臧�瓴� $41.8685搿� 4,600欤�(臧滊硠 瓯半灅 臧�瓴� 氩旍渼: $41.50鈥�$42.36)鞕� 臧�欷戫弶攴� 臧�瓴� $42.6275搿� 400欤�(臧滊硠 瓯半灅 臧�瓴� 氩旍渼: $42.56鈥�$42.83). 氤搓碃霅� 瓯半灅 頉� Form 4鞐愲姅 臧侁皝 86,744欤检檧 86,344欤检潣 鞁れ鞝� 靻岇湢(bene铿乧ial ownership) 靾橃箻臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚胳潃 鞚挫偓搿� 氇呾嫓霅橃柎 鞛堨溂氅�, 毵る弰電� 瓿店皽霅� 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
B. Lynne Parshall, administratrice d'Ionis Pharmaceuticals, a vendu 5,000 actions ordinaires d'Ionis le 08/06/2025 en vertu d'un plan de n茅gociation pr茅茅tabli au titre de la r猫gle 10b5-1 adopt茅 le 6 mai 2025. Les d茅clarations font 茅tat de deux ventes : 4,600 actions 脿 un prix moyen pond茅r茅 de $41.8685 (les prix individuels allant de $41.50 脿 $42.36) et 400 actions 脿 un prix moyen pond茅r茅 de $42.6275 (prix individuels de $42.56 脿 $42.83). 脌 la suite des transactions signal茅es, le Form 4 indique des positions de propri茅t茅 b茅n茅ficiaire de 86,744 actions et 86,344 actions, respectivement. La personne d茅clarante est identifi茅e comme administratrice et les ventes ont 茅t茅 ex茅cut茅es conform茅ment au plan de n茅gociation divulgu茅.
Die Direktorin von Ionis Pharmaceuticals, B. Lynne Parshall, verkaufte am 08/06/2025 5,000 Stammaktien von Ionis im Rahmen eines vorab festgelegten Handelsplans nach Rule 10b5-1, der am 6. Mai 2025 angenommen wurde. Die Meldungen berichten von zwei Verk盲ufen: 4,600 Aktien zu einem gewichteten Durchschnittspreis von $41.8685 (Einzelhandelspreise lagen zwischen $41.50 und $42.36) und 400 Aktien zu einem gewichteten Durchschnittspreis von $42.6275 (Einzelpreise zwischen $42.56 und $42.83). Nach den gemeldeten Transaktionen weist das Form 4 jeweils 86,744 Aktien bzw. 86,344 Aktien als wirtschaftliches Eigentum aus. Die meldende Person ist als Direktorin angegeben, und die Verk盲ufe wurden gem盲脽 dem offengelegten Handelsplan ausgef眉hrt.
FAQ
What insider activity did Ionis (IONS) disclose on this Form 4?
Were the sales by the Ionis director part of a pre-arranged plan?
At what prices were the Ionis shares sold in the Form 4?
How many shares did the reporting person beneficially own after the sales?
